HOME >> MEDICINE >> NEWS
Participation in clinical trials does not appear to affect physician's adherence to guidelines

Physicians who participated in a pharmaceutical-sponsored clinical trial involving asthma medications maintained adherence to treatment guidelines but were more likely to prescribe the sponsor's drugs, according to a study in the June 21 issue of JAMA.

Pharmaceutical companies are frequently involved in clinical trials in general practice, and this may trigger an increase in the use of the sponsoring company's products due to the physicians' experience with these products. This effect may be further strengthened by close physician-company cooperation, which may create physician loyalty toward the company. The effect of participation in company-sponsored studies on drug preferences has not been evaluated in primary care.

Morten Andersen, M.D., Ph.D., of the University of Southern Denmark, Odense, and colleagues investigated the effects of physicians participating in a pharmaceutical company-sponsored clinical trial that was aimed at improving patients' use of asthma medicine. The study compared 10 practices that were conducting the trial on asthma medicine with 165 control (nontrial-conducting) practices in Funen County, Denmark. The study included 5,439 patients treated with asthma drugs from the trial-conducting practices and 59,574 patients from the control practices.

The researchers found that the prevalence of inhaled steroid use among asthma patients increased from 68.5 percent at baseline to 72.9 percent during the second observation year in trial-conducting practices and from 69.1 percent to 73.3 percent in control (nontrial-conducting) practices. There was no impact of participating in the trial on physicians' adherence to international treatment guidelines. Both trial-conducting and control practices had a gradually increased use of the trial sponsor's inhaled corticosteroids, from 74.8 percent to 81.5 percent in trial-conducting practices and from 73.6 percent to 76.6 percent in control practices. Trial-conducting practices were 2
'"/>

Contact: Morten Andersen, M.D., Ph.D.
mandersen@health.sdu.dk
JAMA and Archives Journals
20-Jun-2006


Page: 1 2

Related medicine news :

1. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
2. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators
3. International journal group updates guidelines on registration of clinical trials
4. Urgent need for guidance on mobile phone use in clinical care
5. New prostate cancer clinical guidelines to be released
6. First clinical trial of gene therapy for childhood blindness
7. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
8. Taking the wraps off drug safety data from clinical trials
9. Preclinical results of Geovaxs AIDS vaccines demonstrate potential to protect against disease
10. 30+ AIDS vaccine clinical trials in 24 countries, research occurring on every continent
11. NIH-funded program co-directed by Mailman School of PH faculty to expedite clinical research process

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: